Gao H J, Zhong L J, Yan X Y, Zhang W X, Shen Weixiang
Tongji Hospital, Institute of Digestive Diseases, School of Medicine, Tongji University, Shanghai 200065, China.
China Center for Helicobacter pylori Molecular Medicine, Shanghai 201321, China.
Zhonghua Yi Xue Za Zhi. 2022 Jun 14;102(22):1631-1634. doi: 10.3760/cma.j.cn112137-20220224-00384.
As widespread eradication treatment continues, the rate of () antibiotic resistance is increasing. Together with host CYP2C19 gene polymorphisms, coccoid transformation, patient compliance, irregular treatment regimens or empirical repeated eradication therapy by physician, eradication rates have gradually decreased. Personalized treatment is an effective measure to achieve successful eradication of in the initial treatment. With the first approval of molecular diagnostic kit for clarithromycin resistance in China and the updated definition of refractory infection by the American Gastroenterological Association (AGA), the personalized treatment of guided by antibiotic resistance genotype detection in initial treatment, that follows the latest international consensus and guidelines, conforms to the national situation and surpasses the international standards, has come to the forefront.
随着广泛的根除治疗持续进行,()抗生素耐药率正在上升。连同宿主CYP2C19基因多态性、球菌样转化、患者依从性、不规范的治疗方案或医生的经验性重复根除治疗,根除率已逐渐下降。个性化治疗是在初始治疗中成功根除(原文此处括号内容缺失,无法准确翻译)的有效措施。随着中国首个用于检测克拉霉素耐药性的分子诊断试剂盒获批以及美国胃肠病学会(AGA)对难治性(原文此处括号内容缺失,无法准确翻译)感染定义的更新,在初始治疗中以抗生素耐药基因型检测为指导进行(原文此处括号内容缺失,无法准确翻译)的个性化治疗,遵循最新的国际共识和指南,符合国情且超越国际标准,已成为前沿。